Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.
In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.
Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.
ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.
Therefore, you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
CAR-T for Chronic Lymphocytic Leukemia Receives FDA Approval.
2.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
3.
PSA Screening May Modestly Curb Prostate Cancer Deaths
4.
Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.
5.
Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?
1.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
2.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
3.
Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy
4.
Subarachnoid Hemorrhage: Emerging Insights into Pathophysiology and Future Management
5.
Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL
3.
Navigating the Complexities of Ph Negative ALL - Part XV
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
5.
Efficient Management of First line ALK-rearranged NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation